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ABSTRACT
 
Background: To date, few series on robot-assisted radical prostatectomy (RARP) in kidney 
transplant recipients (KTRs) have been published.
Purpose: To report the experience of two referral centers adopting two different RARP 
approaches in KTRs. Surgical, oncological and functional results were primary outcomes 
evaluated in the study.
Material and methods: We retrospectively analyzed data from 9 KTRs who underwent 
transperitoneal RARP or Retzius-sparing RARP for PCa from October 2012 to April 2016. 
Data were reported as median and interquartile range (IQR). Pre- and postoperative out-
comes were compared by non-parametric Wilcoxon signed-rank test. Significant differenc-
es were accepted when p ≤ 0.05. Overall survival was assessed using Kaplan-Meier method.
Results: Four KTRs underwent a T-RARP and 5 a RS-RARP. Patient median age was 60 (56-
63) years. Charlson comorbidity index was 6 (5-6). Preoperative median PSA was 5.6 (5-15) 
ng / mL. Preoperative Gleason score (GS) was 6 in 5 patients, 7 (3 + 4) in 3, and 8 (4 + 4) 
in one. Pre- and postoperative creatinine were 1.17 (1.1; 1.4) and 1.3 (1.07; 1.57) mg / dL 
(p = 0.237), while eGFR was 66 (60-82) and 62 (54-81) mL / min / 1.73m2 (p = 0.553), re-
spectively. One (11.1%) Clavien-Dindo grade II complication occurred. Two extended tem-
plate lymphadenectomies were performed, both with nodal invasion. These two patients 
experienced a biochemical recurrence and were subjected to RT. Two patients (22.2%) had 
PSMs. Median follow-up was 42 months. Seven patients (77.8%) were continent, 5 (55.6%) 
were potent. Two (22.2%) patients died during follow-up for oncologic unrelated causes.
Conclusions: Our series suggests that both RARP approaches are safe and feasible tech-
niques in KTRs for PCa.
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INTRODUCTION
In the last decades, a longer and qualitati-
vely better life has been granted to kidney trans-
plant recipients (KTRs) (1).
 However, a higher rate of carcinogenesis 
has been described with an increase of the risk of 
malignant transformation by three to five folds 
compared to age-matched controls (2).
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 In these patients, prostate cancer (PCa) 
represents the most common tumor among geni-
tourinary malignancies (3). Despite several series 
have been published, the real incidence of locali-
zed PCa in these cohorts remains unclear, ranging 
from 0.72% to 3.1% (4, 5). Recently, a large po-
pulation of 123.280 transplant recipients has been 
investigated and PCa was identified as the most 
frequent organ-confined neoplasia, diagnosed in 
0.82% patients (6).
 Although different options have been pro-
posed for the treatment of PCa in KTRs, such as 
surgery, radiotherapy and brachytherapy (7), ra-
dical prostatectomy remains the preferred option. 
Reasons in favor of surgery could be ascribed to 
possible complications associated to radiation tre-
atment (RT) in this group of patients (ie. nephritis, 
ureteral anastomosis strictures, avascular necrosis 
of the femoral head).
 To date, few data have been reported 
regarding active surveillance (AS) or watchful 
waiting (WW) for PCa in KTRs (8). However, 
non-active treatments would be perhaps adop-
ted in the future even in this specific low risk 
PCa population.
 Though in small series, almost all appro-
aches for radical prostatectomy have been descri-
bed, including retropubic, transperineal, and lapa-
roscopic (4, 9-11). However, radical prostatectomy 
is more complex in KTRs due to previous peri-
toneal dialysis, transplant surgery, graft location 
and immunosuppression. In 2008, Jhaveri et al. 
described the first robot assisted radical prosta-
tectomy (RARP) in a patient with a kidney graft. 
To our knowledge, only limited series have been 
published about RARP in KTRs (4, 5, 7, 11-15).
 The aim of the current study is to eva-
luate safety, feasibility and efficiency of two di-
fferent RARP techniques in KTRs, performed in 
two high-volume referral centers, and to descri-
be intra- and post-operative outcomes, analyzing 
short- and medium-term follow-up oncological 
and functional outcomes.
MATERIALS AND METHODS
 From October 2012 to May 2016, nine pa-
tients previously subjected to renal transplanta-
tion underwent RARP. Four of them, experienced 
a trans-peritoneal RARP (T-RARP); five a Retzius-
-sparing RARP (RS-RARP); all of them were diag-
nosed with a localized PCa.
 All data were prospectively collected in 
two different customized databases and retrospec-
tively analyzed.
 Baseline demographic features, surgical, 
oncological and functional outcomes were inves-
tigated and complications were evaluated accor-
ding to the Clavien-Dindo scale (16).
 Potency was defined as erections allowing 
satisfying penetrations. Continence recovery was 
assessed according to ICIQ criteria (17).
Description of the techniques
Patients were placed in lithotomy position, 
with a 27 to 30 degrees Trendelemburg inclina-
tion. All pressure points were carefully padded in 
order to avoid vascular and nervous injuries. Be-
fore the port placement, a bladder catheter was 
positioned.
A standardized four-arm robotic confi-
guration was used in all patients, either with the 
robotic da Vinci® Si or Xi systems, both placed 
caudally between the legs: a total of 6 ports were 
used, 3 for the robotic arms, 1 for the camera and 
2 for the bedside assistant (one of 12mm and one 
of 5mm).
The placement of the third robotic arm or 
the 12mm assistant port was modified, medially 
and cranially respect to the standard set, in the 
renal transplant recipients to avoid trauma to the 
graft as represented in Figures 1 and 2.
Lymphadenectomies were carried out ac-
cording to the preoperative risk of lymph node in-
vasion assessed according to the updated Briganti 
nomogram (18).
European Institute of Oncology
In two KTRs, the bedside assistant stood 
on the left side, instead of on the right, to avoid 
trauma to the right positioned kidney graft during 
the laparoscopic instruments insertion.
The peritoneal incision, external to the umbi-
lical ligaments, was tailored according to the trans-
plant side; the remaining procedure was conducted 
equally to our standardized RARP procedure.
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Figure 2 - Robotic and assistant port positioning for RS-RARP.
The placement of the 12 mm assistant port was modifi ed, medially and cranially 
respect to the standard set, in case of right kidney graft location.
 Figure 1 - Robotic and assistant port positioning for T-RARP.
A) The placement of the 12 mm assistant port was modifi ed, medially and cranially respect to the standard set, in case of right kidney graft location. B) The placement of the 
third robotic arm was modifi ed, medially and cranially respect to the standard set, in case of right kidney graft location.
A B
All patients underwent a nerve sparing 
procedure, two patients only anterograde and two 
anterograde and retrograde.
In all patients, a posterior musculo-fascial 
reconstruction after radical prostatectomy was 
performed as described by Coelho et al. (19) and 
no lymphadenectomies were carried out.
Niguarda Hospital
The bedside assistant was placed on the 
right side of the patient. In case of a right-sided 
kidney transplant, the 12mm assistant port was 
placed more cranially. After the docking, the Ret-
zius-sparing surgery was conducted as previou-
sly described (20), without modifi cations from 
the standard protocol: the peritoneal incision was 
performed on the rectovesical pouch, where the 
surgical fi eld was intact from previous surgeries 
and the kidney was placed distant. No posterior 
reconstruction techniques have been used.
One monolateral and one bilateral lympha-
denectomy were performed, adopting an extended 
template. The main limitation in performing a bi-
lateral template was ascribed to the previous ves-
sels dissection and vascular anastomosis for the 
kidney graft. Moreover, our dissection resulted 
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very difficult due to the healing adhesions found 
in the perinodal fat.
Statistical analysis
 Data are reported as median and inter-
quartile range (IQR). Pre- and postoperative ou-
tcomes were compared by non-parametric Wilco-
xon signed-rank test. Significant differences were 
accepted when p ≤ 0.05. Overall survival (OS) was 
assessed using Kaplan-Meier method.
 Statistical analysis was performed using 
SPSS, version 20 (IBM, New York, NY, USA).
RESULTS
 Pre-, intra- and postoperative outcomes 
are showed in Tables 1 and 2. Data are reported 
as median and interquartile range (IQR). Patient 
age at surgery was 60 (56-63) years, with a BMI 
of 25.7 (24.2-27.7) kg / m2. The interval between 
renal transplantation and RARP was 9 years (6-
22): renal graft was sited on the right iliac fossa in 
7 (77.8%) patients and on the left for the remai-
ning 2 (22.2%). Charlson comorbidity index was 6 
(5-6). In the preoperative assessment median PSA 
resulted of 5.6 (5-15) ng / mL, while the clini-
cal stage was T1c in 4 (44.5%) patients, T2a in 3 
(33.3%), T2c and T3b for the remaining two. At 
the prostate biopsy, the Gleason score was establi-
shed as 6 (3 + 3) in 5 (55.6%) patients, 7 (3 + 4) in 
3 (33.3%) patients, and 8 (4 + 4) in the remaining 
one (11.1%). Among the 5 patients diagnosed with 
a GS of 6 (3 + 3), 2 had oncologic characteristic 
adequate for AS according to PRIAS criteria (21), 
but both refused the surveillance program. Due to 
preoperative serum creatinine of 6.7 mg / dL, one 
(11.1%) patient was subjected to hemodialysis the 
day before radical prostatectomy. No significant 
difference was described comparing serum crea-
tinine levels before and after surgery, accounted 
respectively for 1.17 (1.1-1.4) and 1.3 (1.07-1.57) 
mg / dL (p = 0.237). Furthermore, no significant 
difference was described for eGFR calculated as 66 
(60; 82) and 62 (54; 81) mL / min / 1.73m2 res-
pectively before and after surgery (p = 0.553). In 
two (22.2%) patients chronic kidney disease status 
(CKDS) worsened of 1 point after surgery, while 
Table 1-Robotic and assistant port positioning for T-RARP.
Variables
Age, yrs (median, IQR) 60 (56-63)
BMI, kg/m2 (median, IQR) 25.7 (24.2-27.7)
CCI (median, IQR) 6 (5-6)
Time from transplantation, yrs (median, IQR) 9 (6-22)
Creatinine, mg/dL (median, IQR) 1.17 (1.1;1.4)
PSA, ng/mL (median, IQR) 5.6 (5-15)
Gleason score Sum (Nº, %)
(3+3) 5 (55.6%)
(3+4) 3 (33.3%)
(4+4) 1 (11.1%)
Clinical Stage (Nº, %)
T1c 4 (44.5%)
T2a 3 (33.3%)
T2c 1 (11.1%)
T3a 1 (11.1%)
Abbreviations: yrs = Years; IQR= Interquartile range; BMI = Body mass index; CCI = Charlson Comorbidity Index; PSA = Prostate Specific Antigen
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in one (11.1%) patient we detected a 1-point impro-
vement. No intraoperative complications were 
reported. Overall, operating time was 160 (145-
183) minutes, with an estimated blood loss of 100 
(100-200) mL. Six (66.7%) patients were subjec-
ted to a nerve sparing procedure. Prostate weight 
was 40 (39-45) g. Median hemoglobin decrease 
was 2.6 (2.15-3.2) and no blood transfusion was 
necessary. One (11.1%) Clavien-Dindo grade II 
complication was described due to a systemic in-
flammatory syndrome for urinary tract infection. 
The hospital stay consisted in 4 (3-6) days, while 
the days of catheterization were 7 (6-8) days.
Table 2-Robotic and assistant port positioning for RS-RARP.
Variables
Operative time, min (median, IQR) 160 (145-183)
EBL, mL (median, IQR) 100 (100-200)
Length of stay, days (median, IQR) 4 (3-6)
Nº of LADs (Nº, %) 2 (22.2%)
Nº of positive LADs (Nº, %) 2 (22.2%)
Days of catheterization  (median, IQR) 7 (6-8)
Complications by Clavien scale (Nº, %) Grade II: 1 (11.1%)
Gleason score Sum (Nº, %)
(3+3) 4 (44.5%)
(3+4) 3 (33.3%)
(4+3) 2 (22.2%)
Pathologic Stage (Nº, %)
pT2a 1 (11.1%)
pT2c 6 (66.7%)
pT3a 1 (11.1%)
pT3b 1 (11.1%)
PSMs (Nº, %) 2 (22.2%)
BCR (Nº, %) 2 (22.2%)
Potency recovery rate (Nº, %) 5 (55.6%)
Continence recovery rate (Nº, %) 7 (77.8%)
Last follow up serum creatinine, mg/dL (median, IQR) 1 (1-2.7)
Abbreviations: IQR = Interquartile range; EBL = Estimated blood loss; LADs = Lymphadenectomies; PSMs = Positive surgical margins; BCR = Biochemical recurrence 
No changes in immunosuppressive regimes 
were reported in pre- or postoperative periods. Re-
garding calcineurin inhibitors (tacrolimus or cyclos-
porine), serum levels were daily obtained during the 
hospital stay and therapy was adjusted as necessary. 
Pathological analysis reported Gleason score 6 (3 + 3) 
in four patients (44.5%), 7 (3 + 4) in three (33.3%) and 
7 (4 + 3) in the other two (22.2%). One patient (11.1%) 
was pT2a, six patients (66.7%) pT2c, one (11.1%) pT3a 
and the last one (11.1%) pT3b. In two patients an ex-
tended lymph node dissection was performed, and in 
both patients a lymph node invasion was assessed. 
In one case a bilateral lymphadenectomy was perfor-
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med with a lymph node yield of 19 nodes, 3 of them 
positive for neoplastic invasion. In the other case, a 
monolateral lymphadenectomy was conducted with 
a lymph node yield of 3 nodes, 1 of them positive 
for neoplastic invasion. These two patients experien-
ced a biochemical recurrence (BCR) (PSA > 0.2 ng / 
mL) and were subjected to RT. Two patients (22.2%) 
had positive surgical margins, one of them was focal. 
All patients reached at least 12 months of follow-
-up (median 42 months); 7 (77.7%) were continent, 
the remaining 2 patients were affected by a moderate 
incontinence; 2 (22.2%) patients were potent, while 
other 3 (33.3%) of them reached a potency recovery 
with PDE-5 inhibitors administration. At last follow 
up median serum creatinine accounted for 1 (1; 2.7) 
mg / dL, and no significant difference was described 
with pre preoperative one (p = 0.237). Two (22.2%) 
patients died for oncologic unrelated causes.
DISCUSSION
 Although widely debated, a greater inci-
dence of PCa was described in transplanted patients 
(22), with higher frequencies of advanced malig-
nancies and worse disease specific survival (23).
 Moreover, thanks to immunosuppression 
regimen improvements, survival expectancy after 
kidney transplantation has increased of more than 
10 years, (12) enlarging the number of recipients 
older than fifty years old, and making PCa han-
dling as important as in general population (1).
 Generally, alteration of normal tissue’s 
planes caused by previous retroperitoneal surgery 
and pelvic location of kidney graft are frightening 
factors that preclude RT in order to avoid adverse 
events (ie. ureteral stenosis, actinic pyelonephritis 
and gastrointestinal toxicity) (5, 24).
 In 2004, Mouzin et al. published a study 
in which 8 KTRs underwent external beam RT as 
primary therapy for localized PCa. In two patients 
(25%) a significant obstruction of the terminal 
ureter was described, and one patient (12.5%) had 
a decrease in renal graft function (24). Moreover, 
two patients (25%) had BCR after a mean follow-
-up period of 28 months.
 On the contrary, more recently Iizuka et al. 
showed no severe adverse events in 4 KTRs treated 
with RT (5).
 Typically, localized PCa in KTRs had been 
treated performing a radical retropubic-prosta-
tectomy (9). However, a surgical treatment could 
not be thought free from challenges and compli-
cations. Most common hitches were graft injuries, 
including also ureter and vessels, high incidence 
of intraperitoneal adhesions in patient subjected 
to peritoneal dialysis, difficulties in performing a 
vesical-urethral anastomosis due to bladder des-
cent limitation caused by the shortness of trans-
plant ureter (25).
 In 2006, Shah et al. described the first se-
ries of laparoscopic radical prostatectomy (LRP) in 
KTRs (26). Despite some studies depicted LRP as 
safe and feasible in the treatment of PCa in trans-
plant recipients, Robert et al. reported an inciden-
ce of rectal injury clearly higher than in general 
population (22.2 vs. 1.8%, p = 0.022) (27).
 Since its advent, robotic approach over-
came the technical limitations that have charac-
terized the laparoscopic surgery. Particularly in 
presence of pelvic graft, the wristed instruments 
allow for easier suturing and dissection avoiding 
the graft hindrance flexing over it.
 In 2008, Jhaveri et al. reported the first 
case of the RARP in KTRs (4). Since then, few stu-
dies, with small cohort, were published regarding 
the use of robotic approach to treat localized PCa 
in this population (Table-3).
 To our knowledge, our series represents 
the second largest cohort of KTRs treated with 
RARP, and the only multi-institutional study that 
includes two different techniques.
 Despite the aforementioned advantages, 
RARP remains a challenging surgery in these pa-
tients. Several authors have described some te-
chnical modifications necessary to overcome the 
graft’s impediment; for example, Smith et al. and 
Polcari et al. adopted assistant ports placement 
contralateral to renal graft (12, 13), while Ghazi et 
al. and Moreno et al. modified the 6 ports setting 
into a 5 ports arrangement, performing RARP wi-
thout a robotic arm. (7, 14); some others, instead, 
(11, 15) proved the modification of the port sites to 
be useless.
 In our series, during T-RARP assistant, 
ports were placed contralateral to renal graft, and, 
as suggest by Jhaveri et al. (4), the robotic arm on 
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the side of the graft was slightly lifted up in order 
to avoid injuries.
 For the RS-RARP instead, only the robotic 
arm on the side of the graft was moved cranially 
and laterally respect to the standard setting.
 Despite the graft hindrance and the setting 
modifications, we described comparable operative 
times in respect to the standard RARP. Furthermo-
re, no intraoperative complications were reported 
and no blood transfusions were required.
 Previous studies reported variable rate of 
complications (43%), (4, 5, 7, 11-15) maybe results 
of the small samples size, including urosepsis, he-
maturia, atrial fibrillation, conversion to laparo-
tomy.
 In the current study, we reported only a 
single case (11.1%) of urosepsis, promptly resolved 
with appropriate therapy. Noteworthy, no surgical 
or medical injuries were assessed regarding graft 
function. In fact, no significant differences in se-
Table 3-Overall survival Kaplan-Meier curve analysis.
Authors Year Nº of 
patients
Surgical 
approach
Operating 
time, min
Estimated 
blood loss, 
mL
Complications 
Clavien-Dindo
Hospital-
ization, 
days
Catheteriza-
tion, days
PSM, nº 
(%)
BCR, nº 
(%)
Jhaveri 
et al.
2008 1 Transperitoneal 200 400 No 2 7 No No
Smith et 
al.
2011 3 Transperitoneal 322 75 No 2.3 - 1 (33%) NO
Polcari 
et al.
2012 7 Transperitoneal 186 - Grade II: 3
1 Haematuria
1 Urosepsis
1 Atrial 
fibrillation
1.8 8.1 2 
(28.6%)
1 (14.3)
Wagener 
et al.
2012 1 Transperitoneal 220 300 No - (4 weeks) No No
Ghazi et 
al.
2012 1 Transperitoneal 130 125 No - 10 No -
Le Clerc 
et al.
2015 12 Transperitoneal 241 648 - - 3 (27.3) 2 (16.7)
Moreno 
et al.
2015 4 Transperitoneal 196 - 3.2 10 2 (50) 1 (25)
Iizuka et 
al.
2016 3 Transperitoneal 162 52 Grade II: 1 - 9.3 No 1 (33.3)
Mistretta 
et al. 2017 9
Cumulative: 160 100 4 7
T-RARP: 4 170 100 No 5 6 No No
RS-RARP: 5 150 100 Grade II: 1
1 Urosepsis
3 8 2 
(22.2%)
2 (22.2)
Abbreviations: RARP = Robot-assisted radical prostatectomy; T-RARP = Transperitoneal-RARP; RS-RARP = Retzius Sparing-RARP; PSMs = Positive surgical margins; 
BCR = Biochemical recurrence
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rum creatinine levels were observed between pre- 
and postoperative settings (p = 0.237), or at the 
last follow-up (p = 0.237). Similarly, no signifi -
cant differences were found regarding pre- and 
postoperative CKDS status.
 Regarding the oncological outcomes, pa-
thological analysis described a Gleason score 6 (3 
+ 3) in 44.5% of patients, 7 (3 + 4) in 33.3% and 
7 (4 + 3) in the 22.2%, describing 4 upgrading 
and 2 downgrading in respect to Gleason score 
assessed at preoperative prostatic biopsy.
 These data underline the problem of 
RARP for low risk PCa patients, particularly in 
frail patients such as KTRs. Few studies are re-
ported regarding AS for PCa in transplant re-
cipients. In particular, AS was described only 
in one study for one patient with low-risk di-
sease (28), WW in one study for four patients 
in total (29).
 In our series AS was proposed to the two 
patients that satisfi ed preoperative PRIAS criteria 
(21), but both of them refused the surveillance 
program. Although, the immunomodulation and 
the subsequent impaired spontaneous cancer 
control should be considered in this population.
 Despite the short follow-up and the small 
size of the series, our study described oncologic 
outcomes concordant with the ones reported in 
literature. In the general population, PSM rate of 
patient treated with RARP for localized PCa ran-
ged from 14.1% to 29% (30). In the previous stu-
dies regarding RARP in KTRs PSM rate was re-
ported as 0-50% (4, 5, 7, 11-15). In our study two 
patients (22.2%) had a PSM, one of them focal.
 In general population, BCR free survival 
rates at 3 years were reported at 96.3% (31). In 
our study, two patients (22.2%) experienced BCR 
and underwent radiotherapy. These data are simi-
lar to those of previous series of KTRs subjected 
to RARP. Moreover, high PSA levels and palpable 
neoplasia at digital rectal examination had been 
assessed in these two patients before surgery and a 
nodal invasion was determined at fi nal histology.
 Lastly, two patients (22.2%) died due to 
cancer unrelated causes. Curve regarding overall 
survival is showed in Figure-3.
Figure 3 - Overall survival Kaplan-Meier curve analysis. 
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 However, similarly to PSM rate and BCR, 
it is difficult to analyze data regarding survival 
rate, and these high frequencies could be attribu-
ted to the limited number of cases in the series.
 A good continence recovery was described 
in previous studies (4, 7, 11-13). Our data agree 
with the former assessing a complete continence 
recovery of 7 out 9 patients (77.8%). In the remai-
ning two patients a moderate incontinence (17) 
was described. Noteworthy, one of these patients 
was subjected to adjuvant RT influencing the con-
tinence recovery.
 Our study is the first reporting data on 
erectile function recovery. KTRs seem to be as-
sociated with higher rate of erectile dysfunction 
(32). The nerve sparing approach could result even 
more challenging if performed in KTRs.
 In general population, potency recovery 
rate at one year after the surgical procedure was 
assessed ranging from 29.6% to 77.6% (33, 34). 
In the current study 6 patients (66.7%) received a 
nerve-sparing procedure (4 bilateral, 2 monolate-
ral), and 5 (55.6%) achieved a potency recovery, 
with or without PDE5i intake, sufficient to have 
sexual intercourses.
 The current study has some limitations 
due to the small sample size. However, although 
in future the incidence of PCa could increase in 
KTRs, nowadays it remains limited. This issue im-
poses to treat the pathology in referral high volu-
mes centers, by expert surgeons.
 Second limitation is the retrospective na-
ture of the analysis. However, as previously stated 
the rarity of KTRs patients affected by PCa makes 
difficult to complete a randomized prospective 
trial.
CONCLUSIONS
 The current study’s results suggest that 
both RARP approaches adopted at our institu-
tions may be safely applied in KTR patients. A 
low morbidity and overall good surgical outcomes 
were reported without any major complication. 
Oncologic and functional outcomes showed are 
comparable with those of general population pa-
tients subjected to RARP. However, robot-assisted 
radical prostatectomy still remains a challenging 
surgery in KTRs, and should be performed by ex-
pert robotic surgeons, in a tertiary referral center. 
Furthermore, a more consistent patient cohort is 
needed to confirm our results.
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RARP = robot-assisted radical prostatectomy
RS-RARP = Retzius sparing RARP
RT = radiation treatment
T-RARP = transperitoneal RARP
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